TY - JOUR
T1 - Tuberculosis and COVID-19 co-infection
T2 - description of the global cohort
AU - The TB/COVID-19 Global Study Group
AU - Migliori, Giovanni Battista
AU - Casco, Nicolas
AU - Jorge, Alberto Levi
AU - Palmero, Domingo Juan
AU - Alffenaar, Jan Willem
AU - Denholm, Justin
AU - Fox, Greg J.
AU - Ezz, Wafaa
AU - Cho, Jin Gun
AU - Skrahina, Alena
AU - Solodovnikova, Varvara
AU - Bachez, Pierre
AU - Piubello, Alberto
AU - Arbex, Marcos Abdo
AU - Alves, Tatiana
AU - Rabahi, Marcelo Fouad
AU - Pereira, Giovana Rodrigues
AU - Sales, Roberta
AU - Silva, Denise Rossato
AU - Saffie, Muntasir M.
AU - Miranda, Ruth Caamaño
AU - Cancino, Viviana
AU - Carbonell, Monica
AU - Cisterna, Catalina
AU - Concha, Clorinda
AU - Cruz, Arturo
AU - Salinas, Nadia Escobar
AU - Revillot, Macarena Espinoza
AU - Valdés, Joaquín Farías
AU - Fernandez, Israel
AU - Flores, Ximena
AU - Tapia, Patricia Gallegos
AU - Garavagno, Ana
AU - Vera, Carolina Guajardo
AU - Bahamondes, Martina Hartwig
AU - Merino, Luis Moyano
AU - Muñoz, Eduardo
AU - Muñoz, Camila
AU - Navarro, Indira
AU - Subiabre, Jorge Navarro
AU - Ortega, Carlos
AU - Palma, Sofia
AU - Pradenas, Ana María
AU - Pereira, Gloria
AU - Castillo, Patricia Perez
AU - Pinto, Mónica
AU - Pizarro, Rolando
AU - Li, Yang
AU - Akkerman, Onno W.
AU - Tiberi, Simon
N1 - Publisher Copyright:
© 2022 European Respiratory Society. All rights reserved.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes. Methods We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based). Results Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality. Conclusion The data suggest that TB and COVID-19 are a “cursed duet” and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.
AB - Background Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes. Methods We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based). Results Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality. Conclusion The data suggest that TB and COVID-19 are a “cursed duet” and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85126711481&partnerID=8YFLogxK
U2 - 10.1183/13993003.02538-2021
DO - 10.1183/13993003.02538-2021
M3 - Article
C2 - 34764184
AN - SCOPUS:85126711481
SN - 0903-1936
VL - 59
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 3
M1 - 2102538
ER -